COVID-19: US Company, Novavax, Set to Commence Human Trials of 'Recombinant Vaccine' - THISDAYLIVE

  • 📰 THISDAY LIVE
  • ⏱ Reading Time:
  • 33 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 17%
  • Publisher: 51%

Indonesia Berita Berita

Indonesia Berita Terbaru,Indonesia Berita utama

COVID-19: US Company, Novavax, Set to Commence Human Trials of 'Recombinant Vaccine' via thisdaylive

An American biotechnology company, Novavax, is set to commence human trials of COVID-19 vaccine in Australia.

Novavax Research Chief, Dr Gregory Glenn, who spoke during a virtual press conference in Melbourne from Novavax’ headquarters in Maryland, US, said the firm had commenced the first phase of the trial in which 131 volunteers will be tested, adding that the volunteers will be from the cities of Melbourne and Brisbane and that the test will look for early signs of the vaccine’s effectiveness.

Many experimental vaccines are in early stages of testing or will begin testing across China, US, Europe. Vaccines are being created with different technologies, and work in different ways, which gives a possibility of at least one to succeed.

 

Terima kasih atas komentar Anda. Komentar Anda akan dipublikasikan setelah ditinjau.
Berita ini telah kami rangkum agar Anda dapat membacanya dengan cepat. Jika Anda tertarik dengan beritanya, Anda dapat membaca teks lengkapnya di sini. Baca lebih lajut:

 /  🏆 14. in İD

Indonesia Berita Terbaru, Indonesia Berita utama